(Q33390705)

English

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

scientific article

Statements

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial (English)
German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit